Kiniksa Pharmaceuticals
KNSA
160 hedge funds and large institutions have $773M invested in Kiniksa Pharmaceuticals in 2024 Q4 according to their latest regulatory filings, with 19 funds opening new positions, 62 increasing their positions, 58 reducing their positions, and 34 closing their positions.
7% more repeat investments, than reductions
Existing positions increased: 62 | Existing positions reduced: 58
1% less call options, than puts
Call options by funds: $2.39M | Put options by funds: $2.41M
3.65% less ownership
Funds ownership: 97.66% → 94.01% (-3.6%)
9% less funds holding
Funds holding: 176 → 160 (-16)
22% less capital invested
Capital invested by funds: $991M → $773M (-$218M)
44% less first-time investments, than exits
New positions opened: 19 | Existing positions closed: 34
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
B
Braidwell
Stamford,
Connecticut
|
+$12.7M |
| 2 |
Morgan Stanley
New York
|
+$10.6M |
| 3 |
JP Morgan Chase
New York
|
+$6.34M |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
+$6.31M |
| 5 |
Millennium Management
New York
|
+$6.01M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FFM
Fairmount Funds Management
West Conshohocken,
Pennsylvania
|
-$23.1M |
| 2 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$7.56M |
| 3 |
Goldman Sachs
New York
|
-$6.78M |
| 4 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
-$6.17M |
| 5 |
BlackRock
New York
|
-$5.6M |
KNSA Hedge Fund Activity: Q4 2024 in Review
160 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Kiniksa Pharmaceuticals (KNSA) for Q4 2024, worth a combined $773M — down 22% from $991M a quarter earlier.
Sellers outnumbered buyers: 34 funds closed out of KNSA and 19 opened new positions — a net loss of 15 holders — while 58 trimmed existing stakes and 62 added.
The largest buyer was Braidwell, adding an estimated $12.7M. The largest seller was Fairmount Funds Management, cutting an estimated $23.1M.
- 160 institutional investors held Kiniksa Pharmaceuticals (KNSA) as of Q4 2024, down from 176 in Q3 2024.
- Funds reported $773M of Kiniksa Pharmaceuticals stock for Q4 2024, down 22% quarter-over-quarter.
- 19 funds opened new Kiniksa Pharmaceuticals positions in Q4 2024 and 34 closed out, a net change of -15 holders.
- The largest Kiniksa Pharmaceuticals buyer in Q4 2024 was Braidwell, an estimated $12.7M added.
- The largest Kiniksa Pharmaceuticals seller in Q4 2024 was Fairmount Funds Management, an estimated $23.1M sold.
Based on aggregated 13F filings for Q4 2024.